Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

Ludwig Kappos, Mark S. Freedman, Chris H. Polman, Gilles Edan, Hans‐Peter Hartung, David H. Miller, Xavier Montalbán, Frederik Barkhof, Ernst‐Wilhelm Radü, Carola Metzig,

The Lancet Neurology · 2009 · 370 citations · 30 references

DOIFull text

Open access

Concepts

References

30